This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Relative risks of side effects with different NSAIDs

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Upper gastrointestinal toxicity (1):

  • highest risk - azapropazone
  • moderate risk - diclofenac, naproxen, indomethacin
  • lowest risk - ibuprofen, mefenamic acid

Azapropazone is also associated with the highest risk of renal, hepatic, allergic and haematological reactions.

COX-2 are associated with a lower incidence of gastro-intestinal side-effects.

NSAIDs and Cardiovascular Risk

A MeReC review stated that (1):

  • highly selective COX-2 inhibitors (e.g. celecoxib, etoricoxib, lumiracoxib), as a class, are associated with a small excess risk of thrombotic events (about three per 1000 users treated for one year) compared with no treatment, and they are contraindicated for patients with established CV disease
  • traditional NSAIDs may also be associated with an increased risk of thrombotic events. Diclofenac 150mg/day appears to be associated with a similar excess risk to that of cox-2 inhibitors, whereas low-dose ibuprofen (<=1200mg/day) and naproxen 1000mg/day appear to be associated with a lower risk

The risk profiles of NSAID's are continually changing, and the reader is advised to consult the BNF 10.1.1.


  • (1)Prescribers' Journal (1999), 39 (2), 102-8.
  • (2) MeReC Extra 2007;30
  • (3) NICE (July 2000). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.